The University of California, Los Angeles (UCLA) received a $628,499 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) to develop innovative mRNA vaccines for enhancing the efficacy of T-cell transfer therapies against solid tumors, with a focus on pancreatic ductal adenocarcinoma. The research aims to engineer new mRNA vaccines targeting clinically relevant tumor antigens, evaluate the vaccines' safety and efficacy in humanized mouse models, and investigate synergies with KRAS-targeted therapies to reprogram the tumor microenvironment. A sub-award of $173,164 was made to the University of Pennsylvania to support the mRNA vaccine design and production as well as related experiments. The five-year project period runs from August 1, 2024 to July 31, 2029.
Generated 3/18/25, 4:34 AM